Amgen partners to launch biosimilars in China
By 
Rebecca Trager2017-09-29T12:07:00
US biopharma and Chinese generics firm will co-develop medicines from Amgen’s pipeline focused on inflammation and oncology
The US biopharmaceutical firm Amgen and Chinese generic drug maker Simcere Pharmaceutical plan to co-develop and commercialise four biosimilars in China.
Amgen will be responsible for co-development, marketing approval applications and manufacturing of the biosimilars, while Simcere will be in charge of distribution and commercialisation activities in China.